Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers
Author:
Publisher
Frontiers Media SA
Subject
Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry
Reference15 articles.
1. Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology;Criscitiello;Anticancer Agents Med. Chem.,2022
2. Artificial intelligence in breast cancer screening and diagnosis;Dileep;Cureus,2022
3. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer;Fusco;Front. Oncol.,2021
4. Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists;Fusco;Histol. Histopathol.,2021
5. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update;Henry;J. Clin. Oncol.,2022
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment;Future Oncology;2023-12
2. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing;Cancer Treatment Reviews;2023-12
3. Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies;Cancers;2023-11-15
4. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer;Virchows Archiv;2023-09-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3